Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   22/09/2026
39,52 USD (-1,35%)
(-1,35%)   22/09/2026

18 september 2026 · New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients · Persbericht

18 september 2026 · Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs · Persbericht

18 september 2026 · Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults · Persbericht

16 september 2026 · Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care · Persbericht

14 september 2026 · Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy · Persbericht

10 september 2026 · Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes · Persbericht

7 september 2026 · Teva Announces Launch of Offering of Senior Notes · Persbericht

4 september 2026 · S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline · Persbericht

2 september 2026 · Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential · Persbericht

1 september 2026 · Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September · Persbericht

31 augustus 2026 · Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S. · Persbericht

28 augustus 2026 · Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy  · Persbericht

19 augustus 2026 · U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome · Persbericht

11 augustus 2026 · Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy · Persbericht

29 juli 2026 · Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy · Persbericht

9 juli 2026 · Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis · Persbericht

7 juli 2026 · Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results · Persbericht

18 juni 2026 · Teva Releases Q2 2026 Aide Memoire · Persbericht

18 juni 2026 · Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome · Persbericht

18 juni 2026 · Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET · Persbericht

Mijn selecties